Neomics Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neomics Pharmaceuticals - overview
Established
2022
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Founded in 2022 and based in Shanghai, China, Neomics Pharmaceuticals is a medical technology company that focuses on the development of tumor cellular immunotherapy. The founder of the company is Wenshan Hao. The company has a technology platform for the development of new cell therapy drugs. The company's main products include a gene therapy vector micro-loop DNA synthesis method, a tumor infiltrating T-cell in vitro expansion solution, and a novel tri-generation chimeric co-stimulatory receptor-based cell therapy drug.
Current Investors
Shanghai Biomedical Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.